Media coverage about Mesoblast (NASDAQ:MESO) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mesoblast earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.8007755865041 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern’s scoring:
- TiGenix reports 2017 full year results (feeds.benzinga.com)
- Global Autologous Stem Cell Based Therapies Market 2018 – Regeneus, Mesoblast, Pluristem Therapeutics Inc (businessservices24.com)
- MESOBLAST LTD ORDINARY SHARES AUSTRALIA (OTCMKTS:MEOBF) Shorted Shares Increased By 6.06% (nmsuherald.com)
- Mesoblast’s (MESO) Buy Rating Reiterated at Cantor Fitzgerald (americanbankingnews.com)
- Could Mesoblast Limited (MESO) Recover After Forming a Multiple Bottom? (nmsuherald.com)
Shares of Mesoblast stock traded up $0.22 during trading on Thursday, reaching $6.23. The company’s stock had a trading volume of 72,042 shares, compared to its average volume of 61,944. The stock has a market capitalization of $546.19, a price-to-earnings ratio of -6.42 and a beta of 1.95. Mesoblast has a fifty-two week low of $4.74 and a fifty-two week high of $12.50.
A number of equities analysts have recently commented on the stock. Maxim Group reaffirmed a “buy” rating and issued a $14.00 target price on shares of Mesoblast in a report on Wednesday, January 31st. Zacks Investment Research raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a report on Saturday, January 13th. Oppenheimer set a $16.00 target price on shares of Mesoblast and gave the company a “buy” rating in a report on Wednesday, December 20th. Finally, Cantor Fitzgerald set a $23.00 target price on shares of Mesoblast and gave the company a “buy” rating in a report on Wednesday, February 21st. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Mesoblast currently has an average rating of “Hold” and a consensus price target of $13.54.
ILLEGAL ACTIVITY WARNING: This story was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://dakotafinancialnews.com/2018/04/12/mesoblast-meso-getting-somewhat-favorable-press-coverage-study-finds.html.
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.